We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided by Axcelead, in the field of pharmacokinetic and pharmacodynamic analyses (hereinafter referred to as “PK/PD analyses”) and modeling and simulation (hereinafter referred to as “M&S”).
PK/PD analyses and M&S allow the modeling of a potentially large amount of research data, information and findings accumulated in the past, leading to drug candidate evaluation and selection and study design obtained from predictions based on analysis results. In various stages of pharmaceutical research and development, this method has been positioned as an essential technique mainly in Europe and the U.S. as it is thought to lead to an improvement of success rate as well as time and cost reductions due to this process optimization. Currently, the practical and effective introduction of this method in Japan is still in an early stage.
With this in mind, Axcelead, in partnership with LAP&P, a leading M&S company that globally has clients among pharmaceutical and biotech companies, can contribute to a value increase of our clients’ projects by strengthening existing non-clinical M&S offerings and adding new services for clinical M&S and translational research.
Specifically, this business partnership enables integrated PK/PD modeling, including consultation service on M&S, interpretation of pharmacokinetic, drug effect, and biomarker measurement data in non-clinical studies provided by Axcelead, and will give the opportunity to expand to translational research and early clinical studies. In Japan, there is a large scope to expand the more advanced pharmacometrics services, such as physiologically-based pharmacokinetic analysis (PBPK) and quantitative systems pharmacology (QSP) which will be newly provided by the collaboration of the two companies.
Through this business partnership with LAP&P, Axcelead is able to meet various needs of players involved in drug discovery whilst further adding value to clients’ portfolios and contributing to the advancement of drug discovery ecosystem through bridging non-clinical and clinical studies.
Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. and started its business in July 1, 2017. Axcelead has all the functions related to non-clinical drug discovery research and are also able to draw on the scientific powerhouse of our personnel with expertise, deep knowledge and experience in a range of therapeutic areas through their work at Takeda. Axcelead will offer a one stop-shop research services with a comprehensive set of best-in-class capabilities to meet a range of customer needs to bridge basic and applied clinical research, from exploratory research to optimizing compounds.
<About LAP&P Consultants BV>
LAP&P, established in 1999, is a pharmacometrics consulting company based in Leiden (the Netherlands) originating from the Pharmacology faculty of the Leiden University, with Professor Meindert Danhof as one of the cofounders. LAP&P offers modeling and simulation (M&S) services and consulting to support decision making in drug research and development programs. The company offers the whole range from descriptive PK-PD analyses to the most advanced pharmacometric services, such as physiologically-based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) modeling. LAP&P’s pharmacometric services are intended to add value in all stages of drug developement, from exploratory research to late stage clinical development, and to support decisions for different pharmacological subjects, such as drug delivery and bridging from non-clinical to clinical research.
Axcelead Drug Discovery Partners, Inc.
Business Planning and Operations
2-26-1 Muraokahigashi, Fujisawa-shi, Kanagawa 251-0012
LAP&P Consultants BV Archimedesweg 31 2333 CM Leiden
Phone: +31 71 524 3000, Email: firstname.lastname@example.org